caa a22 4500 469073462 CHVBK 20180323132928.0 cr unu---uuuuu 170328e19920101xx s 000 0 eng 10.1007/BF01741051 doi (NATIONALLICENCE)springer-10.1007/BF01741051 Antitumour efficacy of lymphokine-activated killer cells loaded with ricin against experimentally induced lung metastases [Elektronische Daten] [Paola Zanovello, Antonio Rosato, Vincenzo Bronte, Susanna Mandruzzato, Vincenzo Cerundolo, Dino Collavo] Summary: Adoptive transfer of tumour-specific T lymphocytes loaded with ricin into tumour-bearing mice exerts a transient therapeutic effect against locally induced tumours [Cerundolo et al. (1987) Br J Cancer 55: 413]. As transferred cells preferentially locate in the lung, we studied the therapeutic effect of ricin-loaded, lymphokine-activated killer (LAK) cells on lung metastases induced by M4 or B16-F1 (F1) tumour cell injection. In vitro studies demonstrated that ricin-treated LAK cells were about 100-fold more efficient than untreated LAK cells in inhibiting growth of the ricin-sensitive M4 tumour cell line. This effect was most likely due to the released ricin, as treated and untreated LAK cells inhibited the relatively toxin-resistant F1 cell line to the same extent. Ricin treatment did not alter the tissue distribution of intravenously (i.v.) injected LAK cells, which selectively localized in the lung early after inoculation, whether or not metastases were present. Adoptive transfer experiments showed that ricintreated LAK cells were significantly more efficient than untreated LAK cells in inhibiting M4- but not F1-induced lung metastases. These results indicate that LAK cells are able to deliver a therapeutic concentration of antineoplastic compounds directly to the lung. Springer-Verlag, 1992 LAK cells nationallicence Ricin nationallicence Lung metastases nationallicence Zanovello Paola Chair of Immunology, Institute of Oncology, Inter-University Center for Cancer Research, University of Padova, Via Gattamelata 64, I-35128, Padova, Italy aut Rosato Antonio Chair of Immunology, Institute of Oncology, Inter-University Center for Cancer Research, University of Padova, Via Gattamelata 64, I-35128, Padova, Italy aut Bronte Vincenzo Chair of Immunology, Institute of Oncology, Inter-University Center for Cancer Research, University of Padova, Via Gattamelata 64, I-35128, Padova, Italy aut Mandruzzato Susanna Chair of Immunology, Institute of Oncology, Inter-University Center for Cancer Research, University of Padova, Via Gattamelata 64, I-35128, Padova, Italy aut Cerundolo Vincenzo Chair of Immunology, Institute of Oncology, Inter-University Center for Cancer Research, University of Padova, Via Gattamelata 64, I-35128, Padova, Italy aut Collavo Dino Chair of Immunology, Institute of Oncology, Inter-University Center for Cancer Research, University of Padova, Via Gattamelata 64, I-35128, Padova, Italy aut Cancer Immunology, Immunotherapy Springer-Verlag 35/1(1992-01-01), 27-32 0340-7004 35:1<27 1992 35 262 https://doi.org/10.1007/BF01741051 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01741051 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Zanovello Paola Chair of Immunology, Institute of Oncology, Inter-University Center for Cancer Research, University of Padova, Via Gattamelata 64, I-35128, Padova, Italy aut NATIONALLICENCE 700 1- Rosato Antonio Chair of Immunology, Institute of Oncology, Inter-University Center for Cancer Research, University of Padova, Via Gattamelata 64, I-35128, Padova, Italy aut NATIONALLICENCE 700 1- Bronte Vincenzo Chair of Immunology, Institute of Oncology, Inter-University Center for Cancer Research, University of Padova, Via Gattamelata 64, I-35128, Padova, Italy aut NATIONALLICENCE 700 1- Mandruzzato Susanna Chair of Immunology, Institute of Oncology, Inter-University Center for Cancer Research, University of Padova, Via Gattamelata 64, I-35128, Padova, Italy aut NATIONALLICENCE 700 1- Cerundolo Vincenzo Chair of Immunology, Institute of Oncology, Inter-University Center for Cancer Research, University of Padova, Via Gattamelata 64, I-35128, Padova, Italy aut NATIONALLICENCE 700 1- Collavo Dino Chair of Immunology, Institute of Oncology, Inter-University Center for Cancer Research, University of Padova, Via Gattamelata 64, I-35128, Padova, Italy aut NATIONALLICENCE 773 0- Cancer Immunology, Immunotherapy Springer-Verlag 35/1(1992-01-01), 27-32 0340-7004 35:1<27 1992 35 262 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer